Anebulo Pharmaceuticals
Anebulo is a clinical-stage biotechnology company developing novel solutions for people suffering from cannabinoid overdose and substance addiction. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within one hour of administration. Clinical trials completed to date have shown that ANEB-001 is rapidly absorbed, well-tolerated, and leads to weight loss, an effect that is consistent with central cannabinoid receptor type 1 antagonism.
Tech Stack (20 technologies)
Frequently Asked Questions
What technologies does Anebulo Pharmaceuticals use?+
Anebulo Pharmaceuticals uses 20 technologies including Contact Form 7, Google Analytics, Google Tag Manager.
What industry is Anebulo Pharmaceuticals in?+
Anebulo Pharmaceuticals operates in the Biotechnology industry.
Where is Anebulo Pharmaceuticals based?+
Anebulo Pharmaceuticals is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026